Printer Friendly

[CD8.sup.+] T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development?

1. Relevance of Chagas Disease

Trypanosoma cruzi is the etiologic agent of Chagas disease, also known as American trypanosomiasis. Infection with this protozoan parasite currently affects approximately 10 million people (WHO 2013) and is the major cause of nonischemic heart disease worldwide. In Latin America, Chagas disease causes an annual loss of 750,000 years of productivity in addition to a loss of 1.2 billion dollars. Despite the fact that most infected individuals are present in endemic areas of Latin America, an increasing number of cases have been reported outside these areas in recent decades, mainly due to the migratory flux of infected people to other regions. Thus, it is estimated that there are approximately 300,000 currently infected people in the United States, 5,500 in Canada, 80,000 in Europe, 1,500 in Australia, and 3,000 in Japan.

Furthermore, there is no effective chemotherapeutic treatment against this disease. Drugs conventionally used for the treatment of infected individuals were developed in the 1960s (nifurtimox and benznidazole). Being outdated, these drugs are highly toxic, have variable efficacy and weak activity in immunocompromised patients, and require long treatments, and the cost of treatment is high, starting from USD 1,000 per year per patient.

Currently, vectorial control using insecticides is the main method to prevent the transmission. Although vectorial transmission has been controlled in some Southern Cone countries [1] there are reports of insect vector resistance to insecticides in other regions, such as the Gran Chaco [2]. Still, some insect vector species are particularly difficult to control by insecticides; thus, it is likely that control by insecticides will only keep transmission at low levels without eradicating the disease [2].

It should be also noted that vector control does not block transmission by secondary routes, which are the main modes of transmission outside of endemic areas or where the insect vector has been controlled or is absent. The secondary routes are (i) mother to child transmission and blood transfusion and (ii) organ transplantation from infected people. In order to reduce infections by blood or organ transplants, it is critical to analyze donated blood and organs for the presence of parasites [3].

Considering the number of affected people, the economic impact in endemic areas, the recent dispersion of infected people, the inefficiency and cost of treatment, and the lack of effective methods to control transmission, the difficult task of developing a vaccine against infection by Trypanosoma cruzi has been resurrected.

2. Relevance of the Development of a Vaccine for Chagas Disease

In a recent study, Lee et al. generated a computer model to simulate the economic impact of a prophylactic vaccine for Chagas disease in Latin America [4]. This study demonstrated that a vaccine would be beneficial even if it had low protective efficacy (25%), even in places where the risk of becoming infected is less than 1%, and even if the vaccine cost is USD 20.00. A vaccine costing more than USD 200.00 would only be economically advantageous if it had efficacy greater than 50% and was used in places where the risk of becoming infected was greater than 20%. Based on these studies, several groups have been focusing on the development of a vaccine against Chagas disease.

3. Clinical Data of Chagas Disease

Chagas disease has two distinct clinical phases: acute and chronic. In the acute phase, individuals exhibit patent parasitemia that begins one to two weeks after infection. In this phase, the infection has variable symptoms from asymptomatic to intensely symptomatic and includes risk of death. Except Romana sign that is characterized as a swelling at the site of infection, signs and symptoms related to the acute phase of Chagas disease symptoms are most of the times nonspecific and consequently it is difficult to detect the infection in the initial stage. In the acute phase, there is strong activation of the immune system with high levels of plasma cytokines, intense activation of B and T lymphocytes, and inflammatory reactions in the infected tissues (WHO 2013).

In most cases, the acute phase parasitemia is controlled gradually, presumably due to the host adaptive immune responses, and it is reduced to subpatent levels. After controlling acute parasitemia, the chronic phase is initiated. In this phase, it is possible to detect specific antibodies by different serological tests and, in many patients, the parasites can be isolated by blood culture or by xenodiagnosis. These tests are routinely used for parasitological exams (WHO 2013). The chronic phase can last for the entire life of the patient and is initially asymptomatic. After years of initial contact with the parasite, 40% of infected persons develop symptomatology, while the remaining 60% remain asymptomatic throughout life.

In approximately 30% of cases, patients develop cardiac symptoms (associated with severe myocarditis), and in the remaining 10%, there is damage to the digestive system with infiltration of lymphocytes and neuronal degeneration, leading to the development of megacolon or megaesophagus [5]. Despite the fact that the causes of the immunopathology are not precisely known, several evidences indicate that parasite persistence is a critical factor for the development of Chagas disease [5, 6]. Accordingly, extensive destruction and fibrosis of the heart would be a result of the inflammatory reaction required to eliminate the parasites in the tissues [7]. Nevertheless, whether the parasite has to be present within the heart tissue is still a debatable question. Although most studies have found parasites in this tissue by using detection of DNA by PCR, live parasite has not been detected [8].

4. Immune Response During T. cruzi Infection

4.1. Patients with Chagas Disease. In order to establish a successful chronic infection, there must be a balance between parasite multiplication in the tissues and host immune control that will keep the host alive. In this regard, the host immune response is part of the parasite life cycle. Without proper control of the immune response, the host may die, and the parasite life cycle is broken.

During human infection, protective antibodies are mainly directed towards the Gal epitope containing the [alpha]Gal [alpha]1,3-Gal [beta]1,4-GlcNAc, which is present in the majority of mucin glycoproteins on the surface of T. cruzi trypomastigotes [9]. These antibodies are present in high concentrations during the patent infection and the entire chronic phase and are markers for active human infection [10]. These antibodies kill the parasite independently of the presence of complement or cells, and their activity is facilitated by the presence of specific antibodies for the catalytic domain of the TS enzyme that inhibit sialic acid addition to the surface of trypomastigotes [11]. Whether antibodies directed to other parasite targets are also important in immunity against infection remains to be determined.

Specific T lymphocytes against T. cruzi antigens can be detected in most individuals during chronic infection [12]. There is no direct evidence that these cells are important for host resistance. However, it is possible that they exert antiparasitic activities similar to those observed during experimental infection (see below). Events leading to the depression of the immune response, such as acquired immunodeficiency or immunosuppressive treatments (e.g., AIDS), cause relatively rapid onset of symptomatic forms of the disease in some patients with Chagas disease [13]. In some cases, there is reappearance of patent parasitemia, that is, characteristic of the acute stage of infection [14]. Therefore, it seems clear that the adaptive immune response maintains the low levels of parasitemia observed in patients with Chagas disease during the chronic phase.

Comparative studies of the cellular immune responses in patients who develop clinical symptoms, such as chronic chagasic cardiomyopathy (CCC), have led to conflicting results. Some researchers have associated the high production of IFN-[gamma] with CCC [15, 16]. Based on this, polymorphisms in the promoter gene regions that encode BAT-1 and IL-10 anti-inflammatory proteins suggest that production of IFN-[gamma] is more frequent in patients with CCC [17,18]. Additionally, Tregs have been correlated with clinical CCC improvement [19]. Thus, patients able to control the inflammatory response in the myocardium may have less tissue damage and milder disease. In contrast, other groups have suggested the opposite: higher production of proinflammatory cytokines, such as IFN-[gamma] and IL-17, correlates with an improvement in the clinical picture of chronic Chagas disease [20, 21]. In these cases, CCC would develop due to increased expression of molecules that inhibit the activation of specific T lymphocytes, leading to exhaustion of the specific immune response [21,22].

4.2. Experimental Murine Models. In an attempt to identify the molecules and mechanisms associated with resistance to T. cruzi infection, immunologists have employed a number of genetically modified mice. It has been described that resistance to T. cruzi infection requires activation of the innate and adaptive immune responses directed at different stages of parasite development. In the case of the innate immune response, several mechanisms operate in order to partially control multiplication of the parasite. Accordingly, mice that are genetically deficient in Toll-like receptors (TLRs) and their adaptors (MyD88 and TRIF), the NOD-like receptors (NLR), or inflammasome activators are more susceptible to experimental T cruzi infection [5, 23, 24]. These molecules provide signals for the secretion of mediators, such as TNF-[alpha], IFN-[gamma], and IL-12, which in turn are critical for resistance against experimental infection [25]. Upon activation of the innate immune response, there is intense activation of [CD4.sup.+] and [CD8.sup.+] T lymphocytes, as well as B cells. Likewise, in innate immunity, mice genetically deficient in CD4 or CD8 are also extremely susceptible to infection [26]. These T lymphocytes act by producing type 1 cytokines, such as IFN-[gamma]. However, in the case of [CD8.sup.+] T lymphocytes, direct cytotoxicity mediated by perforin may be important for resistance against infection with some strains of T cruzi [27-29]. Finally, in addition to classical innate and adaptive immune responses, NK cells are also activated and produce IFN-[gamma] [30].

5. Role of [CD8.sup.+] T Cells during T. cruzi Infection

5.1. Patient with Chagas Disease. In the cardiac lesions of chronically infected individuals, the inflammatory infiltrate is largely dominated by [CD8.sup.+] T cells with a minor proportion of [CD4.sup.+] T cells, B cells, plasma cells, macrophages, eosinophils, and mast cells [22]. This predominance suggests an important role for [CD8.sup.+] T cells during infection [31-33]. Given the difficulty of obtaining cardiac tissue from chagasic individuals, analysis of the specificity of intracardiac [CD8.sup.+] T lymphocytes from patients with Chagas cardiomyopathy is limited to a single study involving a small group of patients with HLA-A0201 [34]. In this study, it was shown that patients had specific [CD8.sup.+] T lymphocytes to some of the 26 peptides tested from FL-160 or cruzipain antigens in the peripheral blood. In the same study, cells specific for one of the cruzipain peptides were isolated from the cardiac tissue of a patient. Cells with this same specificity were also present in the peripheral circulation [34].

The frequency of specific [CD8.sup.+] T lymphocytes was lower in the peripheral blood of chagasic patients with severe disease than in asymptomatic or mildly symptomatic patients. Furthermore, the stage of differentiation of these T cells was different between these two groups. Patients with severe disease had fewer early memory cells ([CD45RA.sup.-], [CD27.sup.+], and [CD28.sup.+]) and a higher number of late memory cells ([CD45RA.sup.-], [CD27.sup.-], and [CD28.sup.-]). These results suggest that protection against this disease may be associated with an increased frequency of highly competent [CD8.sup.+] T lymphocytes in the early state of differentiation [35]. Infected people in the chronic phase without cardiac symptoms or with mild symptoms had a higher frequency of specific [CD8.sup.+] T lymphocytes producing IFN-[gamma] than people who developed severe symptoms. Therefore, the severity of the disease may be related to the specificity and quality of the [CD8.sup.+] T cell response generated during infection [20]. In addition, because it is a chronic infection and the antigen persists, it is possible that the cellular response is driven to exhaustion [35]. However, this is not the case of the mouse model. One possible explanation is that the murine model has a very short life span when compared to humans, and then, mice do not develop exhausted T cells.

The specificity of the [CD8.sup.+] T lymphocyte response was analyzed, and several TS epitopes restricted to HLA-A0201 were identified. Due to the high degree of polymorphism of the human HLA plus the divergent specific response among different strains of T. cruzi, it is difficult to establish a correlation between the human immune response and resistance to infection [36]. To identify the target specificity of the [CD8.sup.+] T lymphocyte response from patients in the chronic phase, Alvarez et al. (2008) carried out extensive screening of TS-derived peptides predicted to bind common HLA molecules. The most prevalent HLAs in the population were divided into six supertypes comprising one or more HLA alleles present in 95% of the human population irrespective of ethnic origin. The results of this study indicated that promiscuous TS epitopes, which were able to bind to HLA-A02, HLA-A03, and HLA-A24, are the main targets of memory [CD8.sup.+] T lymphocytes in chronic chagasic patients. Responses to these epitopes were detected in 13 of 25 asymptomatic individuals. This approach suggests that a specific set of HLAs restricted to these peptides can be used to measure the functional activity and frequency of [CD8.sup.+] T lymphocytes specific for T. cruzi in a wide variety of patients with Chagas disease without having to perform HLA typing. Furthermore, it was noted by the authors that the frequency of specific [CD8.sup.+] T lymphocytes producing IL-2 was significantly reduced in chronically infected patients [36]. Considering that the parasite load is extremely low in these individuals, the authors proposed that long-term parasite persistence can result in a specific T lymphocyte population with low capacity for self-renewal. While this workwas only focused on the response to TS proteins, thus only examining a fraction of all the possible [CD8.sup.+] T lymphocytes specific for T. cruzi, it is significant that more than 50% of the evaluated subjects responded to at least one TS epitope.

5.2. Experimental Murine Models. A few hours after penetrating the host cell, T. cruzi escapes from the parasitophorous vacuole and enters the cytosol, where it differentiates into amastigotes and begins its replication. Once the parasite is in the cytosol, its secreted antigens become available to be processed and presented via MHC-I [69]. The relevance of [CD8.sup.+] T lymphocytes in immunity against experimental infection with T. cruzi has been demonstrated by different methods. Studies have used [beta]2-microglobulin-deficient mice, which lack cells restricted to MHC-I molecules (such as NK cells and [CD8.sup.+] T lymphocytes), mice deficient in the CD8 molecule, or mice depleted of [CD8.sup.+] T cells using monoclonal antibodies. In all cases, the absence of [CD8.sup.+] T cells leads to extreme susceptibility to experimental infection [5]. Specific [CD8.sup.+] T cells promote resistance to infection by T cruzi through IFN-[gamma], but direct perforin-mediated cytotoxic activity can also play an important role depending on the strain of T. cruzi [5, 27,28].

The mechanisms involved in the processing and presentation of these antigens to [CD8.sup.+] T cells are unknown. There is evidence that [CD11c.sup.+] dendritic cells are important for the initiation of the immune response that occurs in the draining lymph nodes [65, 70]. Afterwards, the [CD8.sup.+] T lymphocytes recirculate and enter the spleen. This requires the expression of the chemotactic receptor S1PR1 (sphingosine 1 phosphate receptor) on the surface of lymphocytes, as egress can be blocked by use of the drug FTY720 [65].

The response of [CD8.sup.+] T lymphocytes during experimental infection with T. cruzi has kinetics distinct from those observed with viruses or bacteria that cause selflimiting infections, such as influenza, LCMV, or Listeria. In these cases, the peak of the immune response measured by the frequency of specific [CD8.sup.+] T lymphocytes is 7 to 15 days [71]. After T. cruzi infection, we and others have observed that the peak of the immune response occurs after approximately 30 days [27, 39, 72, 73]. These delayed kinetics of the immune response most likely allow the parasite to establish tissue infection before they can be eliminated by [CD8.sup.+] T lymphocytes. The precise mechanisms that control this altered kinetics are not known, but we have observed that the parasite load is an important factor controlling the timing of the immune response. Thus, increasing the parasite inoculum leads to acceleration of the parasitemia/infection onset, which in turn triggers acceleration of specific [CD8.sup.+] T lymphocyte generation [73].

In contrast to what is seen in common viral or bacterial infections, we do not observe a marked decrease (contraction) in the immune response. As shown in Figure 1, the frequencies of specific [CD8.sup.+] T cells remain high for long periods of time. Furthermore, the phenotype of these [CD8.sup.+] T lymphocytes is maintained as T effector memory (TEM) cells through this period, and this is linked to parasite persistence. Effective treatment with an antitrypanocidal drug led to the contraction of the number of [CD8.sup.+] T cells and a change in their phenotype to [CD62L.sup.Low] [74].

Importantly, the immune response mediated by [CD8.sup.+] T cells generated after experimental infection does not always allow host survival. Mice from susceptible strains, such A/Sn, uniformly die after infection with few parasites [75]. However, after infection of resistant mice, such as C57BL/6, the immune response mediated by [CD8.sup.+] T lymphocytes protects the animals from death. Nevertheless, these animals are unable to completely eliminate the parasites, which drives them to the chronic phase of infection. Thus, under no circumstances can the immune response mediated by [CD8.sup.+] T lymphocytes eliminate T cruzi. In contrast, genetic vaccination with a DNA plasmid and recombinant adenovirus expressing an immunodominant T. cruzi antigen amastigote surface protein 2 (ASP-2) is able to induce a potent immune response mediated by [CD8.sup.+] T lymphocytes that protects highly susceptible A/Sn mice [28, 76]. These animals not only survive the acute infection but also do not develop chronic Chagas disease and have no detectable circulating parasites. This observation has created a paradox, since both experimental infections and genetic immunizations induce [CD8.sup.+] T cells that are capable of secreting the antiparasitic mediator IFN-[gamma] and mediating potent cytotoxic lymphocyte activity in vivo. To explain this paradox, we hypothesize that the specific [CD8.sup.+] T lymphocytes induced by the adenoviral vector expressing the ASP-2 antigen (AdASP-2) or by experimental infection present distinct properties that either confer immunoprotective ability in the former or prevent an effective response in the latter. In order to identify this factor, we made a detailed comparison of the two immune responses. We observed that there was a high degree of similarity in the immune responses induced by AdASP-2 and by infection with T cruzi. After 19 days, the immune responses had similar magnitudes and were mediated by multifunctional lymphocytes capable of translocating the CD107a molecule to the cell surface as well as accumulating IFN-[gamma] and TNF-[alpha] after in vitro stimulation with cognate peptide [75]. Moreover, these specific lymphocytes were highly cytotoxic in vivo. Among the few differences, there was a markedly accelerated expansion of the [CD8.sup.+] T cell immune response induced by AdASP-2 compared to T cruzi infection [75]. When we evaluated the proliferation of specific [CD8.sup.+] T lymphocytes, we found that a higher frequency of cells proliferated following infection when compared to immunization with AdASP-2 [75]. However, as mentioned above, their frequencies were similar. This discrepancy was explained by a significant increase in the frequency of specific [CD8.sup.+] T lymphocytes with a proapoptotic phenotype in infected animals compared to immunized animals. Therefore, the main difference observed when comparing the two immune responses was the viability (fitness) of specific [CD8.sup.+] T lymphocytes. Whereas immunization with AdASP-2 induced highly viable specific [CD8.sup.+] T cells, infection led to intense expansion and apoptosis. In order to determine the molecular basis for this phenomenon, we analyzed a total of 28 surface molecules, including adhesion molecules, functional markers, and receptors involved in T lymphocyte survival (Figure 2). The main difference observed was that specific [CD8.sup.+] T cells induced by experimental infection showed a higher expression of apoptotic CD95 (Fas) receptor compared with specific [CD8.sup.+] lymphocytes from mice vaccinated with AdASP-2 [75]. Not only these cells expressed high levels of CD95 on the surface, but signaling through this molecule in vitro with anti-CD95 mAb led to their death. In contrast, specific [CD8.sup.+] T lymphocytes induced by vaccination with AdASP-2 were refractory to death induced by anti-CD95 [75].

These striking differences in the quality of the immune response induced by immunization with the AdASP-2 and by T. cruzi infection provide an important basis to explain the suboptimal immune response mediated by [CD8.sup.+] T cells during infection. In addition, this difference may also explain the success of genetic vaccination with recombinant adenoviral vectors. Indeed, concomitant injection of AdASP-2 and T. cruzi led to (i) a strong specific immune response mediated by [CD8.sup.+] T lymphocytes; (ii) lower expression of CD95, which led to resistance to anti-CD95-mediated apoptosis; (iii) protective immunity against experimental infection with T cruzi [77] (Figure 3).

Another important factor that characterizes the immune response mediated by [CD8.sup.+] T lymphocytes during experimental T. cruzi infection in mice is the fact that it is restricted to few epitopes. This occurs despite the great number of possible CD8 epitopes present in the parasite. This phenomenon is called immunodominance. All the immunodominant epitopes described thus far are expressed by members of the TS family of T. cruzi.

Several molecular mechanisms leading to the immunodominance of [CD8.sup.+] T cells during infection are known, some of which are related to the formation of the peptide-MHC-I complex on the surface of APC. The following are important for the formation of these complexes: (i) abundance of the antigen; (ii) availability of APC; (iii) enzymatic processing by proteasomes and other proteolytic enzymes; (iv) translocation of peptides into the endoplasmic reticulum by transporter proteins; (v) binding of peptides to MHC-I. The second group of factors that influence immunodominance are related to the activation of [CD8.sup.+] T lymphocytes: (i) frequency of cell precursors in the repertoire capable of recognizing the peptide-MHC-I complex; (ii) affinity of the T cell receptors; (iii) [CD8.sup.+] T lymphocyte competition by the APC during priming. Other factors, such as regulation of specific immune responses, the ability of pathogens to mutate their recognized epitopes, expression of specific antigens on the different evolutionary stages, modulation of antigen expression at different stages of infection, and direct inhibition of mechanisms involved in the formation of the peptide-MHC-I complex could also theoretically influence immunodominance, but examples have not yet been described.

Due to the genetic restriction by MHC-I molecules in the case of [CD8.sup.+] T cells, 90% of immunodominance is linked to the fact that only 1% of peptides can bind MHC-I with affinity sufficient to induce a response mediated by [CD8.sup.+] T lymphocytes. This is related to the structure of MHC-I rather than the selective pressure by an organism to prevent the host [CD8.sup.+] T lymphocyte response [78]. Because of the genomic complexity of many infectious agents, most studies seeking to define the molecular basis of immunodominance of [CD8.sup.+] T cell-mediated immunity have used viral models. In a review article on immunodominance [79], they illustrate the evolution of immune restriction mediated by [CD8.sup.+] lymphocytes during vaccinia virus infection. The vaccinia genome has the capacity to generate approximately 175,000 peptides of8, 9, or 10 mer (without considering the possibility of alternative sequences of reads and posttranslational modifications). However, only 20% of these peptides are released after processing by the proteasome and other proteases (35,000 peptides). Although transport to the ER via TAP influences the selection of peptides that are made available to bind MHC-I, such transport has little effect on the restriction of epitopes during vaccinia infection, and approximately 30,000 peptides are transported. Even so, approximately 1% of these peptides bind MHC-I (150 peptides). Once the peptide-MHC-I complex is exposed on the surface of the APC, the repertoire of [CD8.sup.+] T lymphocytes can recognize at least 50% of these epitopes (75 peptides). However, only 50 peptides are recognized, and these make up 90% of the response to vaccinia virus. Finally these 50 vaccinia peptides that are recognized during experimental infection, eight represent more than 50% of the [CD8.sup.+] T lymphocyte response observed against infection.

As mentioned above, the antigen targets of the immune response mediated by [CD8.sup.+] T cells during T cruzi experimental infection are of TS family proteins [27, 72, 73, 80, 81] Table 1). The molecular basis and biological significance of immunodominance are unknown. It is possible that the restriction of the number of known parasite epitopes may be important for establishing the necessary balance between the parasite and the host in order to keep the host alive without eliminating the pathogen, thus leading to chronic infection [5, 82]. Immunodominant epitopes vary by T cruzi strain, such that an epitope can be immunodominant during infection with one strain and subdominant with another in genetically identical hosts [39, 72].

Despite evidence of strong immunodominance during T cruzi experimental infection, to date only one study has attempted to determine the cellular/molecular basis for this phenomenon. In this study, it was reported that infected homozygous C57BL/6 mice or heterozygous F1 mice (C57BL/6 X BALB/c) had similar [CD8.sup.+] T lymphocytes responses to the MHC-I [H-2K.sup.b]-restricted epitope VNHRFTLV. In contrast, the immune response to the MHC-I [H-2K.sup.d]-restricted epitope IYNVGQVSI was significantly reduced in heterozygous animals when compared to homozygous BALB/c mice [72]. Such a discrepancy could not be attributed to the [CD8.sup.+] T lymphocyte repertoire or to low MHC-I [H-2K.sup.d] expression on the APC surface of heterozygous mice. This phenomenon, which restricted the immune response and generated strong immunodominance, could be reproduced in other heterozygote strains of mice after infection with T. cruzi. However, there was no difference in the immune responses of homozygote and heterozygote animals following immunization with the AdASP-2 expressing T. cruzi antigen [72]. Finally, in the same study, C57BL/6 mice infected with two different strains of T. cruzi, both the Y and CL-Brener strains, responded to the two immunodominant epitopes simultaneously. Based on these results, it was proposed that the strong immunodominance induced during infection with T cruzi occurred by the competition of [CD8.sup.+] T lymphocytes generated during priming for a limited number of infected APCs. This competition for APC is also called competitive priming or immunodomination and has been reported in some cases of experimental infection [72, 83].

These observations were independently confirmed in studies showing that [CD8.sup.+] T cells of H-[2.sup.a] infected mice recognized a single immunodominant epitope in the ASP-2 antigen. In contrast, [CD8.sup.+] T cells from mice immunized with recombinant genetic vaccines expressing the same T. cruzi antigen recognized two other subdominant epitopes in addition to the immunodominant epitope [84].

Despite the immunoprotective role of [CD8.sup.+] T lymphocytes during the acute phase of experimental T. cruzi infection, recent studies have proposed that a subpopulation of these lymphocytes is eventually responsible for further damage to heart tissue in the chronic phase. These lymphocytes produce perforin, but not IFN-[gamma], and have a greater propensity to migrate to the heart tissue, causing tissue damage leading to CCC [85].

5.3. [CD8.sup.+] T Cell Mediated Immunity for Vaccine Development. Based on the proven antiparasitic activity of [CD8.sup.+] T cells, several groups have tried to elicit specific [CD8.sup.+] T cells for vaccine development against Chagas disease. For that purpose, subunit vaccines based on plasmid DNA, viral, and bacterial vectors were used. The antigens pursued for recombinant vaccines include T. cruzi trans-sialidase, cruzain (a cysteine proteinase), and the amastigote surface proteins 2, 3,4, TcG1, TcG2, TcG4, TSA-1, and Tc24 (review references [23,80,86-90]). In addition to subunit vaccines, other groups are using attenuated parasites [90]. A more detailed list of the vaccination studies performed with subunit vaccines is shown in Table 2. Overall, the results of mouse vaccinations provide strong evidence that the induction of specific [CD8.sup.+] T cells can elicit protective immunity against acute phase symptoms estimated by parasitemia and survival. In some cases, vaccination also reduced or eliminated chronic symptoms in these mouse models.

An important question is whether vaccination can achieve complete parasite elimination from the host. In most protocols of experimental vaccination, residual parasites are still present and are mostly within tissues rather than circulating in the blood. Therefore, vaccination may at least lead to a decrease or cessation in transmission. Vaccinated mice rarely show symptoms of acute or chronic disease. Therefore, even if they carry tissue parasites they will be asymptomatic. This picture resembles the ~60% of chagasic patients who also maintain residual parasites for their entire lives yet still remain asymptomatic (indeterminate form of the disease). Thus, it would be ethical to propose that a satisfactory vaccination goal could be to lower the frequencies of symptomatic individuals even if that means increasing the frequency of asymptomatic individuals.

During our recent studies of genetic immunization, we used the heterologous prime-boost vaccination regimen consisting of priming with plasmid DNA followed by a booster injection with replication defective human adenovirus type 5, both carrying the ASP-2 gene of T. cruzi. In these studies, we observed that our immunization protocol induced TE cells ([CD11a.sup.High], [CD44.sup.High], [CD127.sup.Low], and [CD62L.sup.Low]). These cells formed a stable pool of functional long-lived [CD8.sup.+] TEM cells ([CD11a.sup.High], [CD44.sup.High], [CD127.sup.High], and [CD62L.sup.Low]). Their long-term survival required a functional IL-12/IL-23 signaling pathway. Most relevant for vaccine development was the fact that these cells were resistant to immunological erosion and mediated strong protective immunity against experimental systemic infection with T. cruzi [76].

According to the current immunological paradigm of vaccines, protective immunity is mainly mediated by T central memory (TCM) cells, which proliferate intensely during recall responses. After an infectious challenge, specific TCM cells differentiate to TE cells, proliferate, and eliminate the pathogen. This concept established that, after vaccination, TCM cells act similarly to self-curing viral infections, such as acute LCMV [91].

Based on this paradigm, we evaluated the importance of [CD8.sup.+] T cell differentiation, proliferation, and recirculation to mediate their antiparasitic effects. In our case, we only had a TEM pool to stimulate. We observed that specific TEM cells differentiated into cells with a [KLRG1.sup.High] [CD27.sup.Low] [CD43.sup.Low] [CD183.sup.Low] [T-bet.sup.High] [Eomes.sup.Low] phenotype and were capable of simultaneously producing the antiparasitic mediators IFN-[gamma] and TNF-[alpha]. Subsequently, we observed that the specific [CD8.sup.+] T cells did not participate in a strong anamnestic immune response, and the protective immunity they mediated was insensitive to treatment with the cytostatic toxic agent hydroxyurea, which drastically reduced their proliferation [92].

We also evaluated the importance of T cell recirculation by administering the immunosuppressive drug FTY720 to vaccinated mice after challenge with T cruzi. This drug reduces lymphocyte recirculation by interfering with T cell signaling via sphingosine-1-phosphate receptor-1 (S1Pr1). This interference results in sustained inhibition of S1Pr1 signaling, effectively trapping T cells within the secondary lymphoid without inhibiting T cell activation. FTY720 administration significantly impaired protective immunity, supporting the hypothesis that T cell recirculation is critical for protective immunity [65].

Based on these observations, we propose a model whereby large amounts of antigen-experienced [CD8.sup.+] TEM cells present following heterologous prime-boost vaccination that differentiate and recirculate, rather than proliferate, are critical for protective immunity Figure 4. Recent studies using the murine LCMV infection model reported that [CD8.sup.+] T cells that provide long-term protective immunity are a subpopulation of TEM cells with the same phenotype as our T cells ([CD44.sup.High] [CD62.sup.Low] [KLRG1.sup.High] [CD27.sup.Low] [CD43(1B1).sup.Low] [CD183.sup.Low] [T-bet.sup.High] [Eomes.sup.Low]) and not classical TCM. These cells have limited proliferative ability, recirculate, and are also critical in the resistance to infection with Listeria monocytogenes and vaccinia [93]. Together, these observations point to a novel [CD8.sup.+] T cell population that provides long-term memory and can be used for T cell vaccine development. Additionally, these two observations challenge the paradigm that memory T lymphocytes need to proliferate in order to mediate protective immunity and suggest that recirculation is indeed fundamental. This idea had not been properly explored and may have important implications in the development of new vaccines.

A current limitation of the experimental model of T. cruzi infection is the absence of information about the precise location where [CD8.sup.+] T lymphocytes eliminate infected cells. Because T. cruzi can infect many cell types and cause systemic (or not) infection, it will be important to determine where [CD8.sup.+] T lymphocytes encounter infected cells. The fact that our vaccinated animals were resistant to challenge with T. cruzi infection by different routes (i.p. and s.c.) suggests that it may also be useful for natural infections.

6. Concluding Remarks

Studies on the role of [CD8.sup.+] T cells during T. cruzi infection have elucidated extremely important information regarding the interface of host/T. cruzi interactions and the equilibrium they achieve to establish chronic infection. In addition, they have opened new avenues for the development of a still elusive veterinarian or human vaccine against Chagas disease.

http://dx.doi.org/10.1155/2014/243786

Conflict of Interests

M. M. Rodrigues is named inventor on patent applications covering Trypanosoma cruzi vectored vaccines and immunization regimens. The other authors have no conflict of interests.

Acknowledgments

This work was supported by Grants from Fundafao de Amparo a Pesquisa do Estado de Sao Paulo (2009/06820-4, 2013/13668-0, and 2012/22514-3) and Instituto Nacional de Ciencia e Tecnologia em Vacina (INCTV-CNPq). C. Pontes, M. R. Dominguez, J. Ersching, M. M. Rodrigues, and J. R. Vasconcelos were recipients of fellowship from FAPESP F. Virgilio and M. M. Rodrigues are recipients of fellowships from CNPq.

References

[1] A. Petherick, "Country by country," Nature, vol. 465, no. 7301, pp. S10-S11, 2010.

[2] C. J. Schofield, J. Jannin, and R. Salvatella, "The future of Chagas disease control," Trends in Parasitology, vol. 22, no. 12, pp. 583-588, 2006.

[3] J. R. Coura and P. A. Vinas, "Chagas disease: a new worldwide challenge," Nature, vol. 465, no. 7301, pp. S6-S7, 2010.

[4] B. Y. Lee, K. M. Bacon, D. L. Connor, A. M. Willig, and R. R. Bailey, "The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America," PLoS Neglected Tropical Diseases, vol. 4, no. 12, article e916, 2010.

[5] C. Junqueira, B. Caetano, D. C. Bartholomeu et al., "The endless race between Trypanosoma cruzi and host immunity: Lessons for and beyond Chagas disease," Expert Reviews in Molecular Medicine, vol. 12, article e29, 2010.

[6] R. L. Tarleton, "Chagas disease: a role for autoimmunity?" Trends in Parasitology, vol. 19, no. 10, pp. 447-451, 2003.

[7] J. D. Maya, M. Orellana, J. Ferreira, U. Kemmerling, R. Lopez-Munoz, and A. Morello, "Chagas disease: present status of pathogenic mechanisms and chemotherapy," Biological Research, vol. 43, no. 3, pp. 323-331, 2010.

[8] M. D. Lewis, F. A. Fortes, M. C. Taylor et al., "Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection," Cellular Microbiology, 2014.

[9] I. C. Almeida, S. R. Milani, P. A. J. Gorin, and L. R. Travassos, "Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-[alpha]-galactosyl antibodies," Journal of Immunology, vol. 146, no. 7, pp. 2394-2400, 1991.

[10] A. L. Andrade, C. M. Martelli, R. M. Oliveira et al., "Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up," The American Journal of Tropical Medicine and Hygiene, vol. 71, no. 5, pp. 594-597, 2004.

[11] V. L. Pereira-Chioccola, A. Acosta-Serrano, I. C. de Almeida et al., "Mucin-like molecules form a negatively charged coat that protects Trypanosoma cruzi trypomastigotes from killing by human anti-[alpha]-galactosyl antibodies," Journal of Cell Science, vol. 113, part 7, pp. 1299-1307, 2000.

[12] W. O. Dutra and K. J. Gollob, "Current concepts in immunoregulation and pathology of human Chagas disease," Current Opinion in Infectious Diseases, vol. 21, no. 3, pp. 287-292, 2008.

[13] A. Rocha, A. C. Oliveira de Meneses, A. Moreira da Silva et al., "Pathology of patients with Chagas' disease and acquired immunodeficiency syndrome," The American Journal of Tropical Medicine and Hygiene, vol. 50, no. 3, pp. 261-268, 1994.

[14] A. M. C. Sartori, J. Eluf Neto, E. Visone Nunes et al., "Trypanosoma cruzi parasitemia in chronic Chagas disease: Comparison between human immunodeficiency virus (HIV)-positive and HIV-negative patients," Journal of Infectious Diseases, vol. 186, no. 6, pp. 872-875, 2002.

[15] J. A. S. Gomes, L. M. G. Bahia-Oliveira, M. O. C. Rocha, O. A. Martins-Filho, G. Gazzinelli, and R. Correa-Oliveira, "Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response," Infection and Immunity, vol. 71, no. 3, pp. 1185-1193, 2003.

[16] J. A. S. Gomes, L. M. G. Bahia-Oliveira, M. O. C. Rocha et al., "Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients," Infection and Immunity, vol. 73, no. 12, pp. 7960-7966, 2005.

[17] R. Ramasawmy, E. Cunha-Neto, K. C. Fae et al., "BAT1, a putative anti-inflammatory gene, is associated with chronic chagas cardiomyopathy," Journal of Infectious Diseases, vol. 193, no. 10, pp. 1394-1399, 2006.

[18] G. C. Costa, M. O. da Costa Rocha, P. R. Moreira et al., "Functional IL-10 gene polymorphism is associated with Chagas disease cardiomyopathy," Journal of Infectious Diseases, vol. 199, no. 3, pp. 451-454, 2009.

[19] F. F. de Araujo, D. M. Vitelli-Avelar, A. Teixeira-Carvalho et al., "Regulatory T cells phenotype in different clinical forms of chagas' disease," PLoS Neglected Tropical Diseases, vol. 5, no. 5, article e992, 2011.

[20] S. A. Laucella, M. Postan, D. Martin et al., "Frequency of interferon-[gamma]-producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease," Journal of Infectious Diseases, vol. 189, no. 5, pp. 909-918, 2004.

[21] L. M. Magalhaes, F. N. Villani, M. C. Nunes, K. J. Gollob, M. O. Rocha, and W. O. Dutra, "High interleukin 17 expression is correlated with better cardiac function in human Chagas disease," The Journal of Infectious Diseases, vol. 207, no. 4, pp. 661-665, 2013.

[22] R. J. ArgUello, M. C. Albareda, M. G. Alvarez et al., "Inhibitory receptors are expressed by Trypanosoma cruzi--specific effector T cells and in hearts of subjects with chronic Chagas disease," PloS ONE, vol. 7, no. 5, p. e35966, 2012.

[23] M. M. Rodrigues, A. C. Oliveira, and M. Bellio, "The immune response to Trypanosoma cruzi: role of toll-like receptors and perspectives for vaccine development," Journal of Parasitology Research, vol. 2012, Article ID 507874,12 pages, 2012.

[24] G. K. Silva, F. R. S. Gutierrez, P. M. M. Guedes et al., "Cutting edge: nucleotide-binding oligomerization domain 1-dependent responses account for murine resistance against Trypanosoma cruzi infection," Journal of Immunology, vol. 184, no. 3, pp. 1148-1152, 2010.

[25] S. B. Boscardin, A. C. T. Torrecilhas, R. Manarin et al., "Chagas' disease: an update on immune mechanisms and therapeutic strategies," Journal of Cellular and Molecular Medicine, vol. 14, no. 6, pp. 1373-1384, 2010.

[26] R. L. Tarleton, M. J. Grusby, M. Postan, and L. H. Glimcher, "Trypanosoma cruzi infection in MHC-deficient mice: Further evidence for the role of both class I- and class II-restricted T cells in immune resistance and disease," International Immunology, vol. 8, no. 1, pp. 13-22, 1996.

[27] F. Tzelepis, B. C. G. de Alencar, M. L. O. Penido, R. T. Gazzinelli, P. M. Persechini, and M. M. Rodrigues, "Distinct kinetics of effector [CD8.sup.+] cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice," Infection and Immunity, vol. 74, no. 4, pp. 2477-2481, 2006.

[28] B. C. G. De Alencar, P. M. Persechini, F. A. Haolla et al., "Perforin and gamma interferon expression are required for [CD4.sup.+] and [CD8.sup.+] T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination," Infection and Immunity, vol. 77, no. 10, pp. 4383-4395, 2009.

[29] U. Muller, V. Sobek, S. Balkow et al., "Concerted action of perforin and granzymes is critical for the elimination of Trypanosoma cruzi from mouse tissues, but prevention of early host death is in addition dependent on the FasL/Fas pathway," European Journal of Immunology, vol. 33, no. 1, pp. 70-78, 2003.

[30] C. Une, J. Andersson, M.-. Eloranta, D. Sunnemark, R. A. Harris, and A. Orn, "Enhancement of natural killer (NK) cell cytotoxicity and induction of NK cell-derived interferon-gamma (IFN-[gamma]) display different kinetics during experimental infection with Trypanosoma cruzi" Clinical and Experimental Immunology, vol. 121, no. 3, pp. 499-505, 2000.

[31] M. D. L. Higuchi, L. A. Benvenuti, R. M. Martins, and M. Metzger, "Pathophysiology of the heart in Chagas' disease: current status and new developments," Cardiovascular Research, vol. 60, no. 1, pp. 96-107, 2003.

[32] M. De Lourdes Higuchi, P. S. Gutierrez, V. D. Aiello et al., "Immunohistochemical characterization of infiltrating cells in human chronic chagasic myocarditis: comparison with myocardial rejection process," Virchows Archiv--a Pathological Anatomy and Histopathology, vol. 423, no. 3, pp. 157-160, 1993.

[33] D. DAvila Reis, R. T. Gazzinelli, G. Gazzinelli, and D. G. Colley, "Antibodies to Trypanosoma cruzi express idiotypic patterns that can differentiate between patients with asymptomatic or severe Chagas' disease," Journal of Immunology, vol. 150, no. 4, pp. 1611-1618, 1993.

[34] S. G. Fonseca, H. Moins-Teisserenc, E. Clave et al., "Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD+ epitopes recognized by T cells from chronically Trypanosoma cruzi-infected patients," Microbes and Infection, vol. 7, no. 4, pp. 688-697, 2005.

[35] M. C. Albareda, S. A. Laucella, M. G. Alvarez et al., "Trypanosoma cruzi modulates the profile of memory [CD8.sup.+] T cells in chronic Chagas' disease patients," International Immunology, vol. 18, no. 3, pp. 465-471, 2006.

[36] M. G. Alvarez, M. Postan, D. B. Weatherly et al., "HLA class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease," PLoS Neglected Tropical Diseases, vol. 2, no. 9, article e288, 2008.

[37] M. M. Rodrigues, M. Ribeirao, V. Pereira-Chioccola, L. Renia, and F. Costa, "Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene," Infection and Immunity, vol. 67, no. 8, pp. 3855-3863, 1999.

[38] A. F. S. Araujo, B. C. G. de Alencar, J. R. C. Vasconcelos et al., "CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2," Infection and Immunity, vol. 73, no. 9, pp. 6017-6025, 2005.

[39] D. L. Martin, D. B. Weatherly, S. A. Laucella et al., "CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strainvariant trans-sialidase epitopes," PLoS Pathogens, vol. 2, no. 8, p. e77, 2006.

[40] G. H. Fontanella, K. De Vusser, W. Laroy et al., "Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate," Vaccine, vol. 26, no. 19, pp. 2322-2334, 2008.

[41] D. F. Hoft, C. S. Eickhoff, O. K. Giddings, J. R. C. Vasconcelos, and M. M. Rodrigues, "Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic Trypanosoma cruzi immunity involving [CD8.sup.+] CTL and B cell-mediated cross-priming," Journal of Immunology, vol. 179, no. 10, pp. 6889-6900, 2007

[42] S. I. Cazarla, F. M. Frank, P. D. Becker et al., "Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against trypanosoma cruzi infection," The Journal of Infectious Diseases, vol. 202, no. 1, pp. 136-144, 2010.

[43] B. C. G. de Alencar, A. F. S. Araujo, M. L. O. Penido, R. T. Gazzinelli, and M. M. Rodrigues, "Cross-priming of long lived protective [CD8.sup.+] T cells against Trypanosoma cruzi infection: importance of a TLR9 agonist and [CD4.sup.+] T cells," Vaccine, vol. 25, no. 32, pp. 6018-6027, 2007

[44] B. Wizel, N. Garg, and R. L. Tarleton, "Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection," Infection and Immunity, vol. 66, no. 11, pp. 5073-5081, 1998.

[45] E. Dumonteil, J. Escobedo-Ortegon, N. Reyes-Rodriguez, A. Arjona-Torres, and M. J. Ramirez-Sierra, "Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice," Infection and Immunity, vol. 72, no. 1, pp. 46-53, 2004.

[46] H. Zapata-Estrella, C. Hummel-Newell, G. Sanchez-Burgos et al., "Control of Trypanosoma cruzi infection and changes in T-cell populations induced by a therapeutic DNA vaccine in mice," Immunology Letters, vol. 103, no. 2, pp. 186-191, 2006.

[47] M. Katae, Y. Miyahira, K. Takeda et al., "Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy," Infection and Immunity, vol. 70, no. 9, pp. 4833-4840, 2002.

[48] Y. Miyahira, H. Akiba, M. Katae et al., "Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination," Journal of Immunology, vol. 171, no. 12, pp. 6344-6348, 2003.

[49] F. Costa, G. Franchin, V. L. Pereira-Chioccola, M. Ribeirao, S. Schenkman, and M. M. Rodrigues, "Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice," Vaccine, vol. 16, no. 8, pp. 768-774, 1998.

[50] A. E. Fujimura, S. S. Kinoshita, V L. Pereira-Chioccola, and M. M. Rodrigues, "DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene," Infection and Immunity, vol. 69, no. 9, pp. 5477-5486, 2001.

[51] N. Garg and R. L. Tarleton, "Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection," Infection and Immunity, vol. 70, no. 10, pp. 5547-5555, 2002.

[52] S. B. Boscardin, S. S. Kinoshita, A. E. Fujimura, and M. M. Rodrigues, "Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection," Infection and Immunity, vol. 71, no. 5, pp. 2744-2757, 2003.

[53] B. H. Fralish and R. L. Tarleton, "Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection," Vaccine, vol. 21, no. 21-22, pp. 3070-3080, 2003.

[54] J. R. Vasconcelos, M. I. Hiyane, C. R. F. Marinho et al., "Protective immunity against Trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase," Human Gene Therapy, vol. 15, no. 9, pp. 878-886, 2004.

[55] C. Claser, N. M. Esplndola, G. Sasso, A. J. Vaz, S. B. Boscardin, and M. M. Rodrigues, "Effector-like [CD8.sup.+] T cells in the memory population mediate potent protective immunity," Microbes and Infection, vol. 9, no. 8, pp. 1011-1019, 2007

[56] E. L. V. Silveira, C. Claser, F. A. B. Haolla, L. G. Zanella, and M. M. Rodrigues, "Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease," Clinical and Vaccine Immunology, vol. 15, no. 8, pp. 1292-1300, 2008.

[57] P. Sepulveda, M. Hontebeyrie, P. Liegeard, A. Mascilli, and K. A. Norris, "DNA-based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection," Infection and Immunity, vol. 68, no. 9, pp. 4986-4991, 2000.

[58] L. Planelles, M. C. Thomas, C. Alonso, and M. C. Lopez, "DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection," Infection and Immunity, vol. 69, no. 10, pp. 6558-6563, 2001.

[59] V. Bhatia and N. J. Garg, "Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice," Clinical and Vaccine Immunology, vol. 15, no. 8, pp. 1158-1164, 2008.

[60] A. V. Machado, J. E. Cardoso, C. Claser, M. M. Rodrigues, R. T. Gazzinelli, and O. Bruna-Romero, "Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase," Human Gene Therapy, vol. 17, no. 9, pp. 898-908, 2006.

[61] S. I. Cazorla, P. D. Becker, F. M. Frank et al., "Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi," Infection and Immunity, vol. 76, no. 1, pp. 324-333, 2008.

[62] X. Duan, Y. Yonemitsu, B. Chou et al., "Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2," Vaccine, vol. 27, no. 44, pp. 6154-6159, 2009.

[63] R. T. Nogueira, A. R. Nogueira, M. C. Pereira et al., "Recombinant yellow fever viruses elicit [CD8.sup.+] T cell responses and protective immunity against Trypanosoma cruzi" PLoS ONE, vol. 8, no. 3, Article ID e59347, 2013.

[64] Y. Miyahira, Y. Takashima, S. Kobayashi et al., "Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control trypanosoma cruzi infection," Infection and Immunity, vol. 73, no. 11, pp. 7356-7365, 2005.

[65] M. R. Dominguez, J. Ersching, R. Lemos et al., "Re-circulation of lymphocytes mediated by sphingosine-1-phosphate receptor-1 contributes to resistance against experimental infection with the protozoan parasite Trypanosoma cruzi," Vaccine, vol. 30, no. 18, pp. 2882-2891, 2012.

[66] R. P. A. Barbosa, B. G. Filho, L. I. D. Santos et al., "Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection," PLoS ONE, vol. 8, no. 4, Article ID e61795, 2013.

[67] S. Gupta and N. J. Garg, "TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice," PLoS ONE, vol. 8, no. 3, Article ID e59434, 2013.

[68] S. Gupta, T. S. Silva, J. E. Osizugbo, L. Tucker, H. M. Spratt, and N. J. Garg, "Serum-mediated activation of macrophages reflects TcVac2 vaccine efficacy against chagas disease," Infection and Immunity, vol. 82, no. 4, pp. 1382-1389, 2014.

[69] N. Garg, M. P. Nunes, and R. L. Tarleton, "Delivery by Trypanosoma cruzi of proteins into the MHC class I antigen processing and presentation pathway," Journal of Immunology, vol. 158, no. 7, pp. 3293-3302, 1997

[70] A. M. Padilla, L. J. Simpson, and R. L. Tarleton, "Insufficient TLR activation contributes to the slow development of [CD8.sup.+] T cell responses in Trypanosoma cruzi infection," Journal of Immunology, vol. 183, no. 2, pp. 1245-1252, 2009.

[71] D. Masopust and R. Ahmed, "Reflections on CD8 T-cell activation and memory," Immunologic Research, vol. 29, no. 1-3, pp. 151-160, 2004.

[72] F. Tzelepis, B. C. G. de Alencar, M. L. O. Penido et al., "Infection with Trypanosoma cruzi restricts the repertoire of parasite-specific [CD8.sup.+] T cells leading to immunodominance," The Journal of Immunology, vol. 180, no. 3, pp. 1737-1748, 2008.

[73] F. Tzelepis, P. M. Persechini, and M. M. Rodrigues, "Modulation of CD4+ T cell-dependent specific cytotoxic CD8+ T cells differentiation and proliferation by the timing of increase in the pathogen load," PLoS ONE, vol. 2, no. 4, article e393, 2007

[74] J. M. Bustamante, L. M. Bixby, and R. L. Tarleton, "Drug-induced cure drives conversion to a stable and protective CD8 + T central memory response in chronic Chagas disease," Nature Medicine, vol. 14, no. 5, pp. 542-550, 2008.

[75] J. R. Vasconcelos, O. Bruna-Romero, A. F. Araujo et al., "Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal [CD8.sup.+] T-cell response: reversal by adenoviral vaccine," PLoS Pathogens, vol. 8, no. 5, Article ID e1002699, 2012.

[76] P. O. Rigato, B. C. de Alencar, J. R. C. de Vasconcelos et al., "Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8+ T effector memory cells specific for a human parasite, Trypanosoma cruzi," Infection and Immunity, vol. 79, no. 5, pp. 2120-2130, 2011.

[77] J. R. Vasconcelos, M. R. Dominguez, A. F. Araujo et al., "Relevance of long-lived CD8+T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination," Frontiers in Immunology, vol. 3, article 358, 2012.

[78] S. Istrail, G. G. Sutton, L. Florea et al., "Whole-genome shotgun assembly and comparison of human genome assemblies," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 7, pp. 1916-1921, 2004.

[79] J. W. Yewdell, "Confronting complexity: real-world immunodominance in antiviral [CD8.sup.+] T cell responses," Immunity, vol. 25, no. 4, pp. 533-543, 2006.

[80] Y. Miyahira, "Trypanosoma cruzi infection from the view of [CD8.sup.+] T cell immunity--an infection model for developing T cell vaccine," Parasitology International, vol. 57, no. 1, pp. 38-48, 2008.

[81] R. L. Tarleton, "Immune system recognition of Trypanosoma cruzi" Current Opinion in Immunology, vol. 19, no. 4, pp. 430-434, 2007.

[82] M. M. Rodrigues, B. C. G. de Alencar, C. Claser, and F. Tzelepis, "Immunodominance: a new hypothesis to explain parasite escape and host/parasite equilibrium leading to the chronic phase of Chagas' disease?" Brazilian Journal of Medical and Biological Research, vol. 42, no. 3, pp. 220-223, 2009.

[83] A. Lanzavecchia, "Lack of fair play in the T cell response," Nature Immunology, vol. 3, no. 1, pp. 9-10, 2002.

[84] M. R. Dominguez, E. L. V. Silveira, J. R. C. de Vasconcelos et al., "Subdominant/cryptic CD8 T cell epitopes contribute to resistance against experimental infection with a human protozoan parasite," PLoS ONE, vol. 6, no. 7, Article ID e22011, 2011.

[85] J. C. Silverio, I. R. Pereira, M. D. C. Cipitelli et al., "[CD8.sup.+] T-cells expressing interferon gamma or perforin play antagonistic roles in heart injury in experimental trypanosoma cruzi-elicited cardiomyopathy," PLoS Pathogens, vol. 8, no. 4, Article ID e1002645, 2012.

[86] S. I. Cazorla, F. M. Frank, and E. L. Malchiodi, "Vaccination approaches against Trypanosoma cruzi infection," Expert Review of Vaccines, vol. 8, no. 7, pp. 921-935, 2009.

[87] J. C. Vazquez-Chagoyan, S. Gupta, and N. J. Garg, "Vaccine development against Trypanosoma cruzi and Chagas disease," Advances in Parasitology, vol. 75, pp. 121-146, 2011.

[88] I. Quijano-Hernandez and E. Dumonteil, "Advances and challenges toward a vaccine against Chagas disease," Human Vaccines, vol. 7, no. 11, pp. 1184-1191, 2011.

[89] E. Dumonteil, M. E. Bottazzi, B. Zhan et al., "Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects," Expert Review of Vaccines, vol. 11, no. 9, pp. 1043-1055, 2012.

[90] B. C. Perez and M. A. Basombrio, "Genetically attenuated Trypanosoma cruzi parasites as a potential vaccination tool.," Bioengineered, vol. 3, no. 4, pp. 242-246, 2012.

[91] E. J. Wherry, V. Teichgraber, T. C. Becker et al., "Lineage relationship and protective immunity of memory CD8T cell subsets," Nature Immunology, vol. 4, no. 3, pp. 225-234, 2003.

[92] J. R. Vasconcelos, M. R. Dominguez, and R. L. Neves, "Adenovirus vector-induced [CD8.sup.+] T effector memory cell differentiation and recirculation, but not proliferation, are important for protective immunity against experimental Trypanosoma cruzi infection," Human Gene Therapy, vol. 25, no. 4, pp. 350-363, Apr 2014.

[93] J. Olson, C. McDonald-Hyman, S. Jameson, and S. Hamilton, "Effector -like [CD8.sup.+] T cells in the memory population mediate potent protective immunity," Immunity, vol. 38, no. 6, pp. 1250-1260, 2013.

Fernando dos Santos Virgilio, (1,2) Camila Pontes, (1,2) Mariana Ribeiro Dominguez, (1,2) Jonatan Ersching, (1,2) Mauricio Martins Rodrigues, (1,2) and Jose Ronnie Vasconcelos (1,2,3)

(1) Centro de Terapia Celular e Molecular (CTCMol), UNIFESP-Escola Paulista de Medicina, Rua Mirassol 207, Sao Paulo 04044-010, SP, Brazil

(2) Departmento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de Sao Paulo-Escola Paulista de Medicina, Rua Mirassol 207, Sao Paulo 04044-010, SP, Brazil

(3) Departamento de Biociencias, Instituto de Saude e Sociedade, UNIFESP, Campus Baixada Santista, Santos 11015-020, SP, Brazil

Correspondence should be addressed to Jose Ronnie Vasconcelos; jrcvasconcelos@gmail.com

Received 23 April 2014; Accepted 15 June 2014; Published 1 July 2014

Academic Editor: Edecio Cunha-Neto

TABLE 1: Immunodominant epitopes recognized by murine CD8+
lymphocytes after infection with T. cruzi.

Antigen    Epitope      MHC      T cruzi   Reference
                                 strain

TS        IYNVGQVSI   H-2K (d)      Y        [37]
ASP-2     VNHRFTLV    H-2K (b)      Y        [27]
ASP-2     TEWETGQI    H-2K (k)      Y        [38]
TSA       ANYDFTLV    H-2K (b)   Brazil      [39]
TSA       ANYKFTLV    H-2K (b)   Brazil      [39]

TABLE 2: Summary of the different antigen delivery systems used
for the induction of [CD8.sup.+] T cells against experimental T.
cruzi infection.

Delivery                                Adjuvant           T cruzi
system                                                   antigen/gene

Rec. protein                        Freund's adjuvant         TS
Rec. Protein                             CpG ODN              TS
Rec. Protein                             CpG ODN          Cruzipain
Rec. protein                          Alum/CpG ODN          ASP-2

Plasmid DNA                               None              TSA-1

Plasmid DNA                               IL-12              TSA

Plasmid DNA                               None                TS

Plasmid DNA                               None              ASP-1
Plasmid DNA                               None              ASP-2

Plasmid DNA                               None              ASP-3
Plasmid DNA                               None              ASP-4
Plasmid DNA                               None               CRP
Plasmid DNA                               None              KMP11
Plasmid DNA                               None               Tc24
Plasmid DNA                           IL-12/GM-CSF           TcG1
Plasmid DNA                           IL-12/GM-CSF           TcG2
Plasmid DNA                           IL-12/GM-CSF           TcG4
Rec. adenovirus                           None                TS
                                                            ASP-2
Rec. Salmonella                           None            Cruzipain
Sendai virus                              None              ASP-2
Yellow fever 17D                          None              ASP-2
Rec. adenovirus + Rec. MVA                None               tsa
Plasmid DNA + Rec. Adenovirus             None              ASP-2
Plasmid DNA + Rec. Adenovirus             None              ASP-2
Rec. influenza + Rec. Adenovirus          None              ASP-2
Plasmid + Rec. MVA                    IL-12/GM-CSF        TcG2/TcG4
Plasmid + Rec. protein                IL-12/GM-CSF      TcG1/TcG2/TcG4

Delivery                            Reference
system

Rec. protein                          [40]
Rec. Protein                          [41]
Rec. Protein                          [42]
Rec. protein                          [38]
                                      [43]
Plasmid DNA                           [44]
                                      [45]
                                      [46]
Plasmid DNA                           [47]
                                      [48]
Plasmid DNA                           [49]
                                      [50]
                                      [41]
Plasmid DNA                           [51]
Plasmid DNA                           [51]
                                      [52]
                                      [53]
                                      [54]
                                      [55]
Plasmid DNA                           [56]
Plasmid DNA                           [56]
Plasmid DNA                           [57]
Plasmid DNA                           [58]
Plasmid DNA                           [45]
Plasmid DNA                           [59]
Plasmid DNA                           [59]
Plasmid DNA                           [59]
Rec. adenovirus                       [60]
                                      [60]
Rec. Salmonella                       [61]
Sendai virus                          [62]
Yellow fever 17D                      [63]
Rec. adenovirus + Rec. MVA            [64]
Plasmid DNA + Rec. Adenovirus         [28]
Plasmid DNA + Rec. Adenovirus         [65]
Rec. influenza + Rec. Adenovirus    [65, 66]
Plasmid + Rec. MVA                    [67]
Plasmid + Rec. protein                [68]

Figure 2: Surface molecules expressed by specific [CD8.sup.+] T
lymphocytes following infection with T cruzi and vaccination with
AdASP-2.

Naive [CD8.sup.+] T cells

CD11a    Low
CD11c    Low
CD25     Low
CD27     High
CD43     Low
CD43I    Low
CD44     Low
CD49d    Low
CD69     Low
CD62L    High
CD70     Low
CD95     Low
CD95L    Low
CD122    Low
CD127    High
CD183    Low
CCR5     Low
CCR9     Low
KLRG-1   Low
PD1      Low
CTLA-4   Low
BTLA     Int.
PDL1     Low
TRAIL    Low
TRANCE   Low
LAG-3    Low
PNAD     Low
OX-40    Low

T naive

Specific [CD8.sup.+] T infected

CD11a    High
CD11c    Int.
CD25     Low
CD27     Low
CD43     High
CD43I    High
CD44     High
CD49d    High
CD69     Low
CD62L    Low
CD70     Low
CD95     High
CD95L    Low
CD122    Low
CD127    Low
CD183    Low
CCR5     Low
CCR9     Low
KLRG-1   High
PD1      Low/int.
CTLA-4   Low
BTLA     Low
PDL1     Low
TRAIL    Low
TRANCE   Low
LAG-3    Low
PNAD     Low
OX-40    Low

TE

Specific [CD8.sup.+] T immunized

CD11a    High
CD11c    Low
CD25     Low
CD27     Low
CD43     High
CD43I    High
CD44     High
CD49d    High
CD69     Low
CD62L    Low
CD70     Low
CD95     Low
CD95L    Low
CD122    Int.
CD127    Low
CD183    Low
CCR5     Low
CCR9     Low
KLRG-1   Low/high
PD1      Low/int.
CTLA-4   Low
BTLA     Low
PDL1     Low
TRAIL    Low
TRANCE   Low
LAG-3    Low
PNAD     Low
OX-40    Low

TE
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Virgilio, Fernando dos Santos; Pontes, Camila; Dominguez, Mariana Ribeiro; Ersching, Jonatan; Rodrig
Publication:Mediators of Inflammation
Date:Jan 1, 2014
Words:9897
Previous Article:Interferons and interferon regulatory factors in malaria.
Next Article:IRF5 is a specific marker of inflammatory macrophages in vivo.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters